Clinical Trial Update: Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating ipilimumab and nivolumab for malignant pleural mesothelioma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: COMPLETED